Aside from representing distinct cancers, the AML cell lines differ from the A375 melanoma line insofar as both MV4–11 and HL-60 cells are BRAF wildtype, whereas A375 cells possess the BRAF V600E mutation, the oncogenic driver mutation for which Trm most commonly is used clinically. Here, BRAF is linked to acute myeloid leukemia.